The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Antiobesity carbonic anhydrase inhibitors: a literature and patent review
Abstract
INTRODUCTION: Obesity is ranked as one of the top 10 global health problems and the major concern deriving from it is the exposure of the population to a vast array of chronic pathologies such as cardiovascular and musculoskeletal disorders, type 2 diabetes, cancer, such as colon, breast and endometrial cancer, together with psychological disorders derived from this condition. The discovery that the clinically used anticonvulsants topiramate (TPM) and zonisamide (ZNS) induced weight loss in obese, epileptic patients, afforded the validation of the mitochondrial carbonic anhydrases (CAs, EC 4.2.1.1) VA and VB as targets for the development of antiobesity drugs. AREAS COVERED: This review deals with the scientific and patent literature regarding obesity or obesity-related pathologies, being particularly focused on the use of carbonic anhydrase inhibitors (CAI) such as TPM and ZNS which inhibit the de novo lipogenesis. EXPERT OPINION: There is an urgent need of new drugs for the treatment of obesity. The identification that the mitochondrial CAs are implicated in the de novo lipogenesis allowed to consider selective inhibitors of such enzymes as useful for the development of new antiobesity drugs. Actually TPM was approved 1 year ago for this therapy, whereas ZNS is also an effective such agent. These compounds are the lead molecules in this field and an intense research is on the way in order to develop new compounds based on the selective inhibition of mitochondrial CA isoforms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
Carbonic anhydrases: novel therapeutic applications for inhibitors and activators
Supuran, C. T. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2467 · Cited by 3,192
Self-citationAssociation analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“The genetic and the CNS control in the bodymass gaining should also be mentioned [26,27].”
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Plasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241
Obesity and the Environment: Where Do We Go from Here?
Hill, J. O., Wyatt, H. R., Reed, G. W., & Peters, J. C. (2003) · Science · doi:10.1126/science.1079857 · Cited by 2,180
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998
Supuran, C. T., Scozzafava, A., & Casini, A. (2003) · Medicinal Research Reviews · doi:10.1002/med.10025 · Cited by 1,449
Self-citationAlterio, V., Di Fiore, A., D’Ambrosio, K., Supuran, C. T., & De Simone, G. (2012) · Chemical Reviews · doi:10.1021/cr200176r · Cited by 1,238
Self-citationDrug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
A Randomized Trial of Sugar-Sweetened Beverages and Adolescent Body Weight
Ebbeling, C. B., Feldman, H. A., Chomitz, V. R., Antonelli, T. A., Gortmaker, S. L., Osganian, S. K., & Ludwig, D. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203388 · Cited by 699 · cited 1×
“NHANES III and NHANES clearly showed that the percentage of children and adolescents becoming obese rose from 11% to 15% [3-5].”
Supuran, C. T. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.05.009 · Cited by 616
Self-citationStructure-based drug discovery of carbonic anhydrase inhibitors
Supuran, C. T. (2012) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2012.672983 · Cited by 614
Self-citationElevated plasma ghrelin levels in Prader–Willi syndrome
Cummings, D. E., Clement, K., Purnell, J. Q., Vaisse, C., Foster, K. E., Frayo, R. S., Schwartz, M. W., Basdevant, A., & Weigle, D. S. (2002) · Nature Medicine · doi:10.1038/nm0702-643 · Cited by 600
Carbonic anhydrase inhibitors and their therapeutic potential
Supuran, C. T., & Scozzafava, A. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.5.575 · Cited by 549
Self-citationPYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans
Batterham, R. L., ffytche, D. H., Rosenthal, J. M., Zelaya, F. O., Barker, G. J., Withers, D. J., & Williams, S. C. R. (2007) · Nature · doi:10.1038/nature06212 · Cited by 484
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476 · cited 1×
“Other major side-effects include diarrea, flatulence and abdominal cramping [29,30].”
Anti-obesity drugs: past, present and future
Rodgers, R. J., Tschöp, M. H., & Wilding, J. P. H. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.009621 · Cited by 430
Partial leptin deficiency and human adiposity
Farooqi, I. S., Keogh, J. M., Kamath, S., Jones, S., Gibson, W. T., Trussell, R., Jebb, S. A., Lip, G. Y. H., & O'Rahilly, S. (2001) · Nature · doi:10.1038/35102112 · Cited by 407
WEIBEL, E. K., HADVARY, P., HOCHULI, E., KUPFER, E., & LENGSFELD, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1081 · Cited by 341
Topiramate as an Inhibitor of Carbonic Anhydrase Isoenzymes
Dodgson, S. J., Shank, R. P., & Maryanoff, B. E. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb06047.x · Cited by 316
Leptin at 14 y of age: an ongoing story
Friedman, J. M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26788b · Cited by 272 · cited 1×
“Treatment of severe obese mice lacking the gene for leptin resulted in a sensible weight loss [22].”
Sibutramine: A Review of its Contribution to the Management of Obesity
McNeely, W., & Goa, K. L. (1998) · Drugs · doi:10.2165/00003495-199856060-00019 · Cited by 219
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity
Supuran, C. T., Fiore, A. D., & Simone, G. D. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.2.383 · Cited by 216
Self-citationKovacic, P., Pozos, R. S., Somanathan, R., Shangari, N., & O'Brien, P. J. (2005) · Current Medicinal Chemistry · doi:10.2174/092986705774370646 · Cited by 188
Nishimori, I., Vullo, D., Innocenti, A., Scozzafava, A., Mastrolorenzo, A., & Supuran, C. T. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050483n · Cited by 186
Self-citationSimone, G. D., Fiore, A. D., Menchise, V., Pedone, C., Antel, J., Casini, A., Scozzafava, A., Wurl, M., & Supuran, C. T. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.032 · Cited by 186
Self-citationSafety of Drug Therapies Used for Weight Loss and Treatment of Obesity
Ioannides‐Demos, L. L., Proietto, J., Tonkin, A. M., & McNeil, J. J. (2006) · Drug Safety · doi:10.2165/00002018-200629040-00001 · Cited by 166
Role of cholecystokinin in appetite control and body weight regulation
Little, T. J., Horowitz, M., & Feinle‐Bisset, C. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00212.x · Cited by 159
Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity
Supuran, C. T. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.10.1545 · Cited by 149
Self-citationMitochondrial carbonic anhydrase.
Dodgson, S. J., Forster, R. E., Storey, B. T., & Mela, L. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.9.5562 · Cited by 144
Topiramate Reduces Energy and Fat Gains in Lean (Fa/?) and Obese (fa/fa) Zucker Rats
Picard, F., Deshaies, Y., Lalonde, J., Samson, P., & Richard, D. (2000) · Obesity Research · doi:10.1038/oby.2000.84 · Cited by 132
Mood Stabilization and Weight Loss With Topiramate
Gordon, A., & Price, L. H. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.968a · Cited by 119
A Clinical View of the Obesity Problem
Pi‐Sunyer, X. (2003) · Science · doi:10.1126/science.1082319 · Cited by 118
Role of hepatic carbonic anhydrase in de novo lipogenesis
Lynch, C. J., Fox, H. L., Hazen, S. A., Stanley, B. A., Dodgson, S. J., & LaNoue, K. F. (1995) · Biochemical Journal · doi:10.1042/bj3100197 · Cited by 106
The Role of Ghrelin in the Control of Energy Balance
Kirchner, H., Heppner, K. M., & Tschöp, M. H. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_7 · Cited by 100
What is the prognosis for new centrally-acting anti-obesity drugs?
Heal, D. J., Gosden, J., & Smith, S. L. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.017 · Cited by 70
Obesity Drug Pipeline Not So Fat
Gura, T. (2003) · Science · doi:10.1126/science.299.5608.849 · Cited by 63
Carbonic anhydrase: inhibition results in decreased urea production by hepatocytes
Dodgson, S. J., & Forster, R. E. (1986) · Journal of Applied Physiology · doi:10.1152/jappl.1986.60.2.646 · Cited by 62
Ghrelin levels in young children with Prader-Willi syndrome
Erdie-Lalena, C. R., Holm, V. A., Kelly, P. C., Frayo, R. S., & Cummings, D. E. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.04.011 · Cited by 60
Alterio, V., Monti, S. M., Truppo, E., Pedone, C., Supuran, C. T., & Simone, G. D. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/b926832d · Cited by 58
Self-citationPoulsen, S., Wilkinson, B. L., Innocenti, A., Vullo, D., & Supuran, C. T. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.010 · Cited by 56
Self-citationStaying Slim with Insulin in Mind
Schwartz, M. W. (2000) · Science · doi:10.1126/science.289.5487.2066 · Cited by 53
Vitale, R. M., Pedone, C., Amodeo, P., Antel, J., Wurl, M., Scozzafava, A., Supuran, C. T., & Simone, G. D. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.03.070 · Cited by 42
Self-citation
Cited by
Structure and function of carbonic anhydrases
Supuran, C. T. (2016) · Biochemical Journal · doi:10.1042/bcj20160115 · Cited by 922
Self-citationHow many carbonic anhydrase inhibition mechanisms exist?
Supuran, C. T. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2015.1122001 · Cited by 737
Self-citationZhao, C., Rakesh, K. P., Ravidar, L., Fang, W.-Y., & Qin, H.-L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.017 · Cited by 651
Advances in structure-based drug discovery of carbonic anhydrase inhibitors
Supuran, C. T. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1253677 · Cited by 413
Self-citation
Metadata
- Authors
- Scozzafava, A., Supuran, C. T., & Carta, F.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa Healthcare
- Published
- 2013-04-22
- Volume
- 23
- Issue
- 6
- Pages
- 725-735
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2150627175
- Cited by
- 273
- References
- 46
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.